- Home
- GGT vs ANL Comparison
GGT vs ANL Comparison
Compare GGT & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GGT
- ANL
- Stock Information
- Founded
- GGT 1994
- ANL 2004
- Country
- GGT United States
- ANL Cayman Islands
- Employees
- GGT N/A
- ANL N/A
- Industry
- GGT Trusts Except Educational Religious and Charitable
- ANL
- Sector
- GGT Finance
- ANL
- Exchange
- GGT Nasdaq
- ANL Nasdaq
- Market Cap
- GGT 136.5M
- ANL 115.1M
- IPO Year
- GGT N/A
- ANL 2023
- Fundamental
- Price
- GGT $4.83
- ANL $2.77
- Analyst Decision
- GGT
- ANL Strong Buy
- Analyst Count
- GGT 0
- ANL 2
- Target Price
- GGT N/A
- ANL $9.00
- AVG Volume (30 Days)
- GGT 59.7K
- ANL 29.8K
- Earning Date
- GGT 01-01-0001
- ANL 08-08-2024
- Dividend Yield
- GGT 15.56%
- ANL N/A
- EPS Growth
- GGT N/A
- ANL N/A
- EPS
- GGT 0.83
- ANL N/A
- Revenue
- GGT N/A
- ANL $5,000,000.00
- Revenue This Year
- GGT N/A
- ANL N/A
- Revenue Next Year
- GGT N/A
- ANL N/A
- P/E Ratio
- GGT $6.90
- ANL N/A
- Revenue Growth
- GGT N/A
- ANL N/A
- 52 Week Low
- GGT $4.32
- ANL $1.85
- 52 Week High
- GGT $7.00
- ANL $17.48
- Technical
- Relative Strength Index (RSI)
- GGT 58.21
- ANL 53.97
- Support Level
- GGT $4.58
- ANL $2.50
- Resistance Level
- GGT $4.80
- ANL $3.50
- Average True Range (ATR)
- GGT 0.06
- ANL 0.47
- MACD
- GGT 0.02
- ANL -0.00
- Stochastic Oscillator
- GGT 88.46
- ANL 40.48
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.